Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

This Says Our Favorite Biotech Is Off to the Races

Shares of a promising biotech we recommended back in February 2013 – jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.

Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we’ve made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later…)

  • Featured Story

    The Looming Gold Production Cliff That Will Drive Prices Higher

    Country Canada maple leaf

    In recent years, global gold production has been at or near record levels. The plentiful supplies have led gold bears to argue that the yellow metal's decade-long bull run will end.

    But gold bears are dead wrong.

    In fact, the 'glory days' of gold production may be ending soon.

    That's because some industry experts are beginning to point to a gold "production cliff' that is looming not far in the future.

    And this coming decline in production can mean only one thing: higher gold prices.

    To continue reading, please click here...


    Read More...
  • gold production cliff